Prozac (fluoxetine, lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: Twenty years since its first publication

David T. Wong, Frank P. Bymaster, Eric Engleman

Research output: Contribution to journalArticle

496 Citations (Scopus)

Abstract

In this review, we describe the evolutionary process involved in the discovery of the selective 5-HT uptake inhibitor, fluoxetine, and summarize some of the large body of scientific research performed on fluoxetine in the 20 years since the first publication. The historical background of the proposed involvement of 5-HT in psychiatric disorders and the activity of tricyclic antidepressants in depression is reviewed. The effects of fluoxetine in various in vitro assays and in animal studies including receptor down-regulation, neurochemical and behavioral models are summarized. In addition, the clinical effectiveness of fluoxetine in depression and obsessive compulsive disorders and its potential use in other disorders are examined.

Original languageEnglish (US)
Pages (from-to)411-441
Number of pages31
JournalLife Sciences
Volume57
Issue number5
DOIs
StatePublished - Jun 23 1995
Externally publishedYes

Fingerprint

Fluoxetine
Serotonin Uptake Inhibitors
Antidepressive Agents
Publications
Depression
Tricyclic Antidepressive Agents
Obsessive-Compulsive Disorder
Psychiatry
Assays
Serotonin
Animals
Down-Regulation
Research

Keywords

  • antidepressant
  • fluoxetine
  • inhibitor
  • Prozac
  • serotonin
  • uptake

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology

Cite this

Prozac (fluoxetine, lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug : Twenty years since its first publication. / Wong, David T.; Bymaster, Frank P.; Engleman, Eric.

In: Life Sciences, Vol. 57, No. 5, 23.06.1995, p. 411-441.

Research output: Contribution to journalArticle

@article{4e3848b3cb4b4731a3a5d6acb12a393f,
title = "Prozac (fluoxetine, lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: Twenty years since its first publication",
abstract = "In this review, we describe the evolutionary process involved in the discovery of the selective 5-HT uptake inhibitor, fluoxetine, and summarize some of the large body of scientific research performed on fluoxetine in the 20 years since the first publication. The historical background of the proposed involvement of 5-HT in psychiatric disorders and the activity of tricyclic antidepressants in depression is reviewed. The effects of fluoxetine in various in vitro assays and in animal studies including receptor down-regulation, neurochemical and behavioral models are summarized. In addition, the clinical effectiveness of fluoxetine in depression and obsessive compulsive disorders and its potential use in other disorders are examined.",
keywords = "antidepressant, fluoxetine, inhibitor, Prozac, serotonin, uptake",
author = "Wong, {David T.} and Bymaster, {Frank P.} and Eric Engleman",
year = "1995",
month = "6",
day = "23",
doi = "10.1016/0024-3205(95)00209-O",
language = "English (US)",
volume = "57",
pages = "411--441",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Prozac (fluoxetine, lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug

T2 - Twenty years since its first publication

AU - Wong, David T.

AU - Bymaster, Frank P.

AU - Engleman, Eric

PY - 1995/6/23

Y1 - 1995/6/23

N2 - In this review, we describe the evolutionary process involved in the discovery of the selective 5-HT uptake inhibitor, fluoxetine, and summarize some of the large body of scientific research performed on fluoxetine in the 20 years since the first publication. The historical background of the proposed involvement of 5-HT in psychiatric disorders and the activity of tricyclic antidepressants in depression is reviewed. The effects of fluoxetine in various in vitro assays and in animal studies including receptor down-regulation, neurochemical and behavioral models are summarized. In addition, the clinical effectiveness of fluoxetine in depression and obsessive compulsive disorders and its potential use in other disorders are examined.

AB - In this review, we describe the evolutionary process involved in the discovery of the selective 5-HT uptake inhibitor, fluoxetine, and summarize some of the large body of scientific research performed on fluoxetine in the 20 years since the first publication. The historical background of the proposed involvement of 5-HT in psychiatric disorders and the activity of tricyclic antidepressants in depression is reviewed. The effects of fluoxetine in various in vitro assays and in animal studies including receptor down-regulation, neurochemical and behavioral models are summarized. In addition, the clinical effectiveness of fluoxetine in depression and obsessive compulsive disorders and its potential use in other disorders are examined.

KW - antidepressant

KW - fluoxetine

KW - inhibitor

KW - Prozac

KW - serotonin

KW - uptake

UR - http://www.scopus.com/inward/record.url?scp=0029029578&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029029578&partnerID=8YFLogxK

U2 - 10.1016/0024-3205(95)00209-O

DO - 10.1016/0024-3205(95)00209-O

M3 - Article

C2 - 7623609

AN - SCOPUS:0029029578

VL - 57

SP - 411

EP - 441

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

IS - 5

ER -